Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri- vs Intra-operative Aflibercept for DME in Cataract Surgery
NCT03920878Phase 2Withdrawn
- Sponsor
- Emory University
- Start
- May 2020
- Primary completion
- Jun 2020
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised trial of aflibercept in diabetic macular edema (DME) (2 arms), sponsored by Emory University. Primary endpoint: Change in best-corrected visual acuity at 6 months. Planned start May 2020; status: withdrawn.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03920878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920878.